JP2023536067A5 - - Google Patents
Info
- Publication number
- JP2023536067A5 JP2023536067A5 JP2023503171A JP2023503171A JP2023536067A5 JP 2023536067 A5 JP2023536067 A5 JP 2023536067A5 JP 2023503171 A JP2023503171 A JP 2023503171A JP 2023503171 A JP2023503171 A JP 2023503171A JP 2023536067 A5 JP2023536067 A5 JP 2023536067A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- expression cassette
- vector
- slc13a5
- aav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055795P | 2020-07-23 | 2020-07-23 | |
| US63/055,795 | 2020-07-23 | ||
| PCT/US2021/042930 WO2022020697A1 (en) | 2020-07-23 | 2021-07-23 | Optimized slc13a5 genes and expression cassettes and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536067A JP2023536067A (ja) | 2023-08-23 |
| JP2023536067A5 true JP2023536067A5 (cg-RX-API-DMAC7.html) | 2024-07-09 |
Family
ID=79728993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503171A Pending JP2023536067A (ja) | 2020-07-23 | 2021-07-23 | 最適化されたslc13a5遺伝子および発現カセットならびにそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230285595A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4700126A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023536067A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3186207A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3057565T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022020697A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240342314A1 (en) * | 2021-09-30 | 2024-10-17 | The Board Of Regents Of The University Of Texas System | Slc13a5 gene therapy vectors and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5587308A (en) * | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
| AU4645697A (en) | 1996-09-11 | 1998-04-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Aav4 vector and uses thereof |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| DE69939169D1 (de) | 1998-05-28 | 2008-09-04 | Us Gov Health & Human Serv | Aav5 vektoren und deren verwendung |
| AU774706B2 (en) | 1998-09-22 | 2004-07-08 | Johns Hopkins University, The | Methods for large-scale production of recombinant AAV vectors |
| DE69936104T2 (de) | 1998-11-05 | 2008-01-17 | The Trustees Of The University Of Pennsylvania | Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten |
| EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| AU6814901A (en) | 2000-06-01 | 2001-12-11 | Univ North Carolina | Methods and compounds for controlled release of recombinant parvovirus vectors |
| US7465583B2 (en) * | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| US20050095240A1 (en) * | 2002-11-22 | 2005-05-05 | Medical College Of Georgia Research | NaCT as a target for lifespan expansion and weight reduction |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| PL2900686T3 (pl) | 2012-09-28 | 2021-01-25 | The University Of North Carolina At Chapel Hill | Wektory aav ukierunkowane na oligodendrocyty |
| AU2015349759B2 (en) | 2014-11-21 | 2022-01-06 | The University Of North Carolina At Chapel Hill | Aav vectors targeted to the central nervous system |
| WO2017180587A2 (en) * | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2017191274A2 (en) * | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| JP2019517274A (ja) * | 2016-06-13 | 2019-06-24 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill | 最適化されたcln1遺伝子および発現カセットおよびそれらの使用 |
| EP3692158A4 (en) * | 2017-10-03 | 2021-08-04 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| US20240342314A1 (en) * | 2021-09-30 | 2024-10-17 | The Board Of Regents Of The University Of Texas System | Slc13a5 gene therapy vectors and uses thereof |
-
2021
- 2021-07-23 EP EP25214109.8A patent/EP4700126A3/en active Pending
- 2021-07-23 EP EP21845857.8A patent/EP4185700B1/en active Active
- 2021-07-23 CA CA3186207A patent/CA3186207A1/en active Pending
- 2021-07-23 WO PCT/US2021/042930 patent/WO2022020697A1/en not_active Ceased
- 2021-07-23 JP JP2023503171A patent/JP2023536067A/ja active Pending
- 2021-07-23 US US18/006,278 patent/US20230285595A1/en active Pending
- 2021-07-23 ES ES21845857T patent/ES3057565T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7374119B2 (ja) | 減少した肝臓向性を有するAAV9とAAVrh74とのハイブリッド組換えアデノ随伴ウイルス血清型 | |
| JP7607007B2 (ja) | 変異aav、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法 | |
| AU2017227803B2 (en) | Therapy for frontotemporal dementia | |
| KR102527259B1 (ko) | 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법 | |
| JP2022141670A5 (cg-RX-API-DMAC7.html) | ||
| RU2653444C2 (ru) | Композиции вектора aav и способы переноса генов в клетки, органы и ткани | |
| CN116096431A (zh) | 肽修饰的aav衣壳 | |
| JP2021532812A5 (cg-RX-API-DMAC7.html) | ||
| JP2022500066A5 (cg-RX-API-DMAC7.html) | ||
| JP2021502060A5 (cg-RX-API-DMAC7.html) | ||
| JP2023514242A5 (cg-RX-API-DMAC7.html) | ||
| Miyake et al. | Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors | |
| TW201629225A (zh) | 第九因子基因療法 | |
| IL262852B1 (en) | Treatment of complement-mediated disorders | |
| JP2022530824A5 (cg-RX-API-DMAC7.html) | ||
| JP2021533805A5 (cg-RX-API-DMAC7.html) | ||
| RU2018145010A (ru) | Оптимизированные гены и экспрессионные кассеты cln1, и их применение | |
| US11891616B2 (en) | Transgene cassettes designed to express a human MECP2 gene | |
| JP2023537980A5 (cg-RX-API-DMAC7.html) | ||
| JP7691367B2 (ja) | Cln3ポリヌクレオチドのアデノ随伴ウイルス送達 | |
| JP2025513066A5 (cg-RX-API-DMAC7.html) | ||
| JP2021533801A5 (cg-RX-API-DMAC7.html) | ||
| CN113574176A (zh) | 腺相关病毒对cln6多核苷酸的递送 | |
| CA3178591A1 (en) | Immunosuppressive agents and viral delivery re-dosing methods for gene therapy | |
| JP2022530264A5 (cg-RX-API-DMAC7.html) |